SCHOLAR ROCK HOLDING CORPORATION Proceeds from Issuance of Debt
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Proceeds from Issuance of Debt of $197.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION proceeds from issuance of debt for the quarter ending 2026-06-30 was $1.05M.
- SCHOLAR ROCK HOLDING CORPORATION proceeds from issuance of debt for the quarter ending 2026-03-31 was $196.68M.
- SCHOLAR ROCK HOLDING CORPORATION proceeds from issuance of debt for the quarter ending 2025-12-31 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION proceeds from issuance of debt for the quarter ending 2025-09-30 was $49.99M.
- SCHOLAR ROCK HOLDING CORPORATION proceeds from issuance of debt for fiscal 2025 was $49.99M.
- SCHOLAR ROCK HOLDING CORPORATION proceeds from issuance of debt for fiscal 2021 was $24.98M, a 1.47% increase from fiscal 2020.
- SCHOLAR ROCK HOLDING CORPORATION proceeds from issuance of debt for fiscal 2020 was $24.62M.
| Period end | Proceeds from Issuance of Debt | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $197.73M 10-Q · filed 2026-08-06 | $197.73M derived: sum of 3 quarters · filed 2026-08-06 | $247.72M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $196.68M 10-Q · filed 2026-05-07 | $196.68M derived: sum of 2 quarters · filed 2026-05-07 | $246.68M derived: sum of 3 quarters · filed 2026-05-07 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $49.99M derived: sum of 2 quarters · filed 2026-03-03 | $49.99M 10-K · filed 2026-03-03 | ||
| 2025-09-30 | $49.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $49.99M 10-Q · filed 2025-11-14 | |||
| 2025-09-29 | $100.00M 10-Q · filed 2026-08-06 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | ||||
| 2021-12-31 | $24.98M 10-K · filed 2023-03-07 | ||||
| 2020-12-31 | $24.62M 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |